Vanguard Group’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-355,162
| Closed | -$369K | – | 4237 |
|
|
2019
Q1 | $369K | Sell |
355,162
-132
| -0% | -$107 | ﹤0.01% | 3824 |
|
|
2018
Q4 | $266K | Sell |
355,294
-656,062
| -65% | -$988K | ﹤0.01% | 3846 |
|
|
2018
Q3 | $2.14M | Buy |
1,011,356
+9,716
| +1% | +$23.3K | ﹤0.01% | 3505 |
|
|
2018
Q2 | $2.31M | Sell |
1,001,640
-245
| -0% | -$713 | ﹤0.01% | 3455 |
|
|
2018
Q1 | $3.19M | Buy |
1,001,885
+3,738
| +0.4% | +$10.3K | ﹤0.01% | 3305 |
|
|
2017
Q4 | $4.09M | Sell |
998,147
-29,417
| -3% | -$128K | ﹤0.01% | 3202 |
|
|
2017
Q3 | $4.64M | Buy |
1,027,564
+31,918
| +3% | +$129K | ﹤0.01% | 3150 |
|
|
2017
Q2 | $3.31M | Buy |
995,646
+50,161
| +5% | +$208K | ﹤0.01% | 3226 |
|
|
2017
Q1 | $8.71M | Buy |
945,485
+45,494
| +5% | +$400K | ﹤0.01% | 2821 |
|
|
2016
Q4 | $6.94M | Buy |
899,991
+88,022
| +11% | +$809K | ﹤0.01% | 2904 |
|
|
2016
Q3 | $9.28M | Buy |
811,969
+179,876
| +28% | +$2.09M | ﹤0.01% | 2723 |
|
|
2016
Q2 | $7.78M | Buy |
632,093
+31,165
| +5% | +$378K | ﹤0.01% | 2768 |
|
|
2016
Q1 | $6.08M | Buy |
600,928
+165,172
| +38% | +$1.94M | ﹤0.01% | 2864 |
|
|
2015
Q4 | $9.82M | Buy |
435,756
+5,109
| +1% | +$105K | ﹤0.01% | 2647 |
|
|
2015
Q3 | $7.14M | Buy |
430,647
+42,178
| +11% | +$846K | ﹤0.01% | 2797 |
|
|
2015
Q2 | $8.74M | Buy |
388,469
+25,659
| +7% | +$633K | ﹤0.01% | 2751 |
|
|
2015
Q1 | $9.35M | Buy |
362,810
+81,367
| +29% | +$2.06M | ﹤0.01% | 2681 |
|
|
2014
Q4 | $6.12M | Buy |
281,443
+40,737
| +17% | +$834K | ﹤0.01% | 2786 |
|
|
2014
Q3 | $4.56M | Buy |
240,706
+63,893
| +36% | +$1.28M | ﹤0.01% | 2884 |
|
|
2014
Q2 | $4.12M | Buy |
176,813
+26,265
| +17% | +$649K | ﹤0.01% | 2942 |
|
|
2014
Q1 | $5.07M | Buy |
150,548
+45,519
| +43% | +$1.53M | ﹤0.01% | 2821 |
|
|
2013
Q4 | $3.1M | Buy |
105,029
+7,899
| +8% | +$145K | ﹤0.01% | 3016 |
|
|
2013
Q3 | $1.49M | Buy |
+97,130
| New | +$1.8M | ﹤0.01% | 3252 |
|
Vanguard Group's OMED Position: Q2 2019 in Review
Vanguard Group sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 355,162 shares — an estimated $369K sold.
Vanguard Group first reported a position in OMED in Q3 2013 and held it in 23 quarters. The position peaked at $9.82M in Q4 2015. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.
- Vanguard Group reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
- Vanguard Group sold 355,162 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $369K.
- Vanguard Group first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 23 quarters.
- Vanguard Group's OncoMed Pharmaceuticals, Inc. position peaked at $9.82M in Q4 2015.
- 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.
Based on Vanguard Group's 13F filing for Q2 2019, filed 14 Aug 2019.